Reimbursement and economic factors influencing dialysis modality choice around the world

被引:118
作者
Just, Paul M. [1 ]
de Charro, Frank Th. [2 ]
Tschosik, Elizabeth A. [3 ]
Noe, Les L. [3 ]
Bhattacharyya, Samir K. [1 ]
Riella, Miguel C. [4 ]
机构
[1] Baxter Healthcare Corp, Div Renal, Mcgaw Pk, IL 60085 USA
[2] Erasmus Univ, NL-3000 DR Rotterdam, Netherlands
[3] ICON Lifecycle Sci Grp, Chicago, IL 60661 USA
[4] Catholic Univ Parana, BR-80240030 Curitiba, Parana, Brazil
关键词
cost; economics; haemodialysis; peritoneal dialysis; reimbursement;
D O I
10.1093/ndt/gfm939
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 [基础医学]; 1002 [临床医学]; 100602 [中西医结合临床];
摘要
The worldwide incidence of kidney failure is on the rise and treatment is costly; thus, the global burden of illness is growing. Kidney failure patients require either a kidney transplant or dialysis to maintain life. This review focuses on the economics of dialysis. Alternative dialysis modalities are haemodialysis (HD) and peritoneal dialysis (PD). Important economic factors influencing dialysis modality selection include financing, reimbursement and resource availability. In general, where there is little or no facility or physician reimbursement or payment for PD, the share of PD is very low. Regarding resource availability, when centre HD capacity is high, there is an incentive to use that capacity rather than place patients on home dialysis. In certain countries, there is interest in revising the reimbursement structure to favour home-based therapies, including PD and home HD. Modality selection is influenced by employment status, with an association between being employed and PD as the modality choice. Cost drivers differ for PD and HD. PD is driven mainly by variable costs such as solutions and tubing, while HD is driven mainly by fixed costs of facility space and staff. Many cost comparisons of dialysis modalities have been conducted. A key factor to consider in reviewing cost comparisons is the perspective of the analysis because different costs are relevant for different perspectives. In developed countries, HD is generally more expensive than PD to the payer. Additional research is needed in the developing world before conclusive statements may be made regarding the relative costs of HD and PD.
引用
收藏
页码:2365 / 2373
页数:9
相关论文
共 76 条
[1]
Financial outcomes in transplantation - A provider's perspective [J].
Abecassis, MM .
AMERICAN JOURNAL OF TRANSPLANTATION, 2006, 6 (06) :1257-1263
[2]
BLAKE P, 2004, REPLACEMENT RENAL FU
[3]
BLOEMBERGEN WE, 1995, J AM SOC NEPHROL, V6, P177
[4]
Bruns FJ, 1998, J AM SOC NEPHROL, V9, P884
[5]
Differences in quality of life across renal replacement therapies: A meta-analytic comparison [J].
Cameron, JI ;
Whiteside, C ;
Katz, J ;
Devins, GM .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2000, 35 (04) :629-637
[6]
Economics of dialysis and renal transplantation in the developing world [J].
Chugh, KS ;
Jha, V ;
Chugh, S .
TRANSPLANTATION PROCEEDINGS, 1999, 31 (08) :3275-3277
[7]
The direct and indirect economic costs incurred by living kidney donors - a systematic review [J].
Clarke, Katherine S. ;
Klarenbach, Scott ;
Vlaicu, Sorina ;
Yang, Robert C. ;
Garg, Amit X. .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 (07) :1952-1960
[8]
Mortality risks of peritoneal dialysis and hemodialysis [J].
Collins, AJ ;
Hao, WL ;
Xia, H ;
Ebben, JP ;
Everson, SE ;
Constantini, EG ;
Ma, JZ .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 34 (06) :1065-1074
[9]
Correa-Rotter R, 2001, PERITON DIALYSIS INT, V21, pS314
[10]
Healthcare systems and end-stage renal disease (ESRD) therapies - an international review: costs and reimbursement/funding of ESRD therapies [J].
De Vecchi, AF ;
Dratwa, M ;
Wiedemann, ME .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1999, 14 :31-41